Pharma BD Deal Intelligence

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. / Green Valley Pharmaceutical Co., Ltd.

2025 · Acquisition/Merger · $199M · Pending

Fosun Pharma announced on 15 December 2025 that its subsidiary Fosun Pharma Industrial, via a special-purpose vehicle, would invest approximately RMB 1.412 billion to acquire a controlling 53% stake in Shanghai-based Green Valley Pharmaceutical. The transaction brings GV-971 (sodium oligomannate), China's conditionally approved oligosaccharide therapy for mild-to-moderate Alzheimer's disease, into Fosun's CNS pipeline. Green Valley's manufacture of GV-971 has been suspended since November 2024 following expiry of its drug registration certificate.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals